Contribute Try STAT+ Today
Trending:
Coronavirus
Health
First Opinion
Biotech

STAT+ Latest

Columns: Adam’s TakePharmalot

Topics: BiotechPharmaPolicyHealth TechBusiness

Features: STAT+ Conversations CRISPR TrackrDrug Pricing Policy TrackerWebinars

Events: See upcoming events

Biotech

Fibrogen’s data manipulation scandal came with questions. There need to be answers

By Adam Feuerstein

expanding claims databases
Opinions+

The many benefits of expanding the reach of state all-payer claims databases

By John Freedman

Biden
Pharmalot

Most Americans believe Biden is correct to support an IP waiver for Covid-19 vaccines

By Ed Silverman

GlaxoSmithKline (GSK) Vaccines
Pharmalot

A clinical trial coordinator is indicted for falsifying data in a Glaxo asthma drug study

By Ed Silverman

TJ Parker
Health Tech

‘More Amazon and less pharmacy’: one exec on the company’s strategy for prescription drugs

By Kate Sheridan

Eric Schmidt at MIT
Health Tech

Watch: Former Google CEO Schmidt opens up on health data privacy and the future of tech in medicine

By STAT staff

Ginkgo Bioworks 05
Biotech

Ginkgo plans a $17.5 billion merger with SPAC that took DraftKings public

By Jonathan Saltzman and Anissa Gardizy — Boston Globe

Pharmalot

Pharmalittle: Key Dems push Pelosi to seek ‘bipartisan’ drug pricing reform; AstraZeneca CEO pay upsets shareholders

By Ed Silverman

Zantac
Pharmalot

Sanofi is accused of ‘widespread destruction’ of company e-mails tied to Zantac recall

By Ed Silverman

patient equation patient friction coefficient
Opinions+

‘Induced proximity’ is why I am optimistic about treating undruggable diseases

By Raymond Deshaies

Telehealth Lobbyists Illustration
Politics

Telehealth companies are fueling a lobbying frenzy to protect their Covid boom

By Rachel Cohrs and Casey Ross

Pelosi - October 2019
Exclusive

Key House Democrats’ push for a ‘bipartisan’ drug pricing bill could doom Pelosi’s signature legislation

By Nicholas Florko

Dana Farber Cancer Institute exterior
Health

Dana-Farber receives $50 million gift to study pancreatic cancer

By Priyanka Dayal McCluskey — Boston Globe

Pharmalot

Pharmalittle: U.K. says IP waiver is insufficient for Covid-19 vaccine access; EU sues AstraZeneca over vaccine supply — again

By Ed Silverman

Smartphone & medicine illustration
Health Tech

Inside Pear’s ambitious plan to become the most dominant player in digital therapeutics

By Mario Aguilar

Pharmalot

Dutch advisory group says Zolgensma shouldn’t be covered unless Novartis halves price

By Ed Silverman

Noubar Afeyan
Biotech

Flagship startup Laronde hopes to use ‘endless RNA’ to produce new treatments

By Anissa Gardizy — Boston Globe

Pharmalot

Pharmalittle: Novavax sees delay in seeking emergency use of its Covid-19 shot; AstraZeneca CEO’s pay causes a stink

By Ed Silverman

HHS Xavier Becerra
Hospitals

HHS plans to open up billions in hospital Covid-19 grants in coming weeks

By Rachel Cohrs

patient experience
Opinions+

The pharma industry needs to measure patient experience from the patients’ perspectives

By Hensley Evans and Sharon Suchotliff

team care puzzle
Health Tech

Why health tech companies are investing so heavily in care teams

By Erin Brodwin

Eli Broad
In Memoriam

Eli Broad’s medical research legacy will ‘touch almost the whole world’

By Bryan Marquard — Boston Globe and Jonathan Saltzman — Boston Globe

Magnifying glass
Pharma

WHO, international regulatory group urge pharma to publish clinical study reports

By Ed Silverman

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

The underdog
Health

How David beat Goliath: Advocacy groups seized a moment, and found allies, in bid to loosen vaccine patent rights

By Lev Facher and Nicholas Florko

MODERNA - Norwood facility
Biotech

Moderna’s CEO says he ‘didn’t lose a minute of sleep’ over potential waiver of vaccine patents

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 shot; EU is willing to explore Covid-19 IP waiver

By Ed Silverman

pill dollar sign list price
Biotech

Two drug makers, two commercial launches — with divergent results

By Adam Feuerstein

Natural Killer Cell
Biotech

CRISPR Therapeutics, Nkarta to jointly develop engineered natural killer cells as cancer treatments

By Adam Feuerstein